Literature DB >> 21256906

Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection.

Marija Zeremski1, Giles Hooker2, Marla A Shu3, Emily Winkelstein3, Queenie Brown1, Don C Des Jarlais4, Leslie H Tobler5, Barbara Rehermann6, Michael P Busch7, Brian R Edlin3, Andrew H Talal8.   

Abstract

BACKGROUND & AIMS: Characterization of inflammatory mediators, such as chemokines, during acute hepatitis C virus (HCV) infection might shed some light on viral clearance mechanisms.
METHODS: Plasma levels of CXCR3 (CXCL9-11)- and CCR5 (CCL3-4)-associated chemokines, ALT, and HCV RNA were measured in nine injection drug users (median 26 samples/patient) before and during 10 acute (eight primary and two secondary) HCV infections. Using functional data analysis, we estimated smooth long-term trends in chemokine expression levels to obtain the magnitude and timing of overall changes. Residuals were analyzed to characterize short-term fluctuations.
RESULTS: CXCL9-11 induction began 38-53days and peaked 72-83days after virus acquisition. Increases in ALT levels followed a similar pattern. Substantial negative auto-correlations of chemokine levels at 1 week lags suggested substantial week-to-week oscillations. Significant correlations were observed between CXCL10 and HCV RNA as well as ALT and CXCR3-associated chemokines measured in the preceding week, CCL3-4 expression levels did not change appreciably during acute HCV infection.
CONCLUSIONS: Elevation of CXCR3-associated chemokines late during acute HCV infection suggests a role for cellular immune responses in chemokine induction. Week-to-week oscillations of HCV RNA, chemokines, and ALT suggest frequent, repeated cycles of gain and loss of immune control during acute hepatitis C.
Copyright © 2011 European Association for the Study of the Liver. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21256906      PMCID: PMC3094733          DOI: 10.1016/j.jhep.2010.12.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  23 in total

1.  Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees.

Authors:  Marian E Major; Harel Dahari; Kathleen Mihalik; Montserrat Puig; Charles M Rice; Avidan U Neumann; Stephen M Feinstone
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

2.  Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.

Authors:  Andrea R Stacey; Philip J Norris; Li Qin; Elizabeth A Haygreen; Elizabeth Taylor; John Heitman; Mila Lebedeva; Allan DeCamp; Dongfeng Li; Douglas Grove; Steven G Self; Persephone Borrow
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

Review 3.  The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.

Authors:  M Zeremski; L M Petrovic; A H Talal
Journal:  J Viral Hepat       Date:  2007-10       Impact factor: 3.728

4.  Cross-genotype immunity to hepatitis C virus.

Authors:  Robert E Lanford; Bernadette Guerra; Deborah Chavez; Catherine Bigger; Kathleen M Brasky; Xiao-Hong Wang; Stuart C Ray; David L Thomas
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

5.  HCV persistence and immune evasion in the absence of memory T cell help.

Authors:  Arash Grakoui; Naglaa H Shoukry; David J Woollard; Jin-Hwan Han; Holly L Hanson; John Ghrayeb; Krishna K Murthy; Charles M Rice; Christopher M Walker
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

6.  Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.

Authors:  Robert Thimme; Jens Bukh; Hans Christian Spangenberg; Stefan Wieland; Janell Pemberton; Carola Steiger; Sugantha Govindarajan; Robert H Purcell; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-19       Impact factor: 11.205

7.  Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.

Authors:  Marija Zeremski; Lydia M Petrovic; Luis Chiriboga; Queenie B Brown; Herman T Yee; Milan Kinkhabwala; Ira M Jacobson; Rositsa Dimova; Marianthi Markatou; Andrew H Talal
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

Review 8.  Innate immune evasion by hepatitis C virus and West Nile virus.

Authors:  Brian C Keller; Cynthia L Johnson; Andrea Kaup Erickson; Michael Gale
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-16       Impact factor: 7.638

Review 9.  Immunological determinants of the outcomes from primary hepatitis C infection.

Authors:  J Post; S Ratnarajah; A R Lloyd
Journal:  Cell Mol Life Sci       Date:  2009-03       Impact factor: 9.261

Review 10.  Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence.

Authors:  Barbara Rehermann
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

View more
  25 in total

1.  Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection.

Authors:  Suganya Selvarajah; Sheila Keating; John Heitman; Kai Lu; Graham Simmons; Philip J Norris; Eva Operskalski; James W Mosley; Michael P Busch
Journal:  J Gen Virol       Date:  2012-04-25       Impact factor: 3.891

2.  Hepatic serum amyloid A1 aggravates T cell-mediated hepatitis by inducing chemokines via Toll-like receptor 2 in mice.

Authors:  Young Rae Ji; Hei Jung Kim; Ki Beom Bae; Sanggyu Lee; Myoung Ok Kim; Zae Young Ryoo
Journal:  J Biol Chem       Date:  2015-04-06       Impact factor: 5.157

3.  Natural history of HCV infection.

Authors:  Shiv K Sarin; Manoj Kumar
Journal:  Hepatol Int       Date:  2012-03-09       Impact factor: 6.047

4.  Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.

Authors:  Marija Zeremski; Rositsa B Dimova; Samantha Benjamin; Marina S Penney; Martyn C Botfield; Andrew H Talal
Journal:  J Infect Dis       Date:  2014-12-15       Impact factor: 5.226

5.  Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.

Authors:  Jason Grebely; Jordan J Feld; Tanya Applegate; Gail V Matthews; Margaret Hellard; Alana Sherker; Kathy Petoumenos; Geng Zang; Ineke Shaw; Barbara Yeung; Jacob George; Suzy Teutsch; John M Kaldor; Vera Cherepanov; Julie Bruneau; Naglaa H Shoukry; Andrew R Lloyd; Gregory J Dore
Journal:  Hepatology       Date:  2013-05-08       Impact factor: 17.425

6.  Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes.

Authors:  Jessica Brownell; Jessica Wagoner; Erica S Lovelace; Derek Thirstrup; Isaac Mohar; Wesley Smith; Silvia Giugliano; Kui Li; I Nicholas Crispe; Hugo R Rosen; Stephen J Polyak
Journal:  J Hepatol       Date:  2013-06-12       Impact factor: 25.083

7.  IP-10 can be measured in dried plasma spots in patients with chronic hepatitis C infection.

Authors:  Morten Ruhwald; Ellen Sloth Andersen; Peer Brehm Christensen; Belinda Klemmensen Moessner; Nina Weis
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

8.  A simple method to quantitate IP-10 in dried blood and plasma spots.

Authors:  Martine G Aabye; Jesper Eugen-Olsen; Anne Marie Werlinrud; Line Lindebo Holm; Tamara Tuuminen; Pernille Ravn; Morten Ruhwald
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

Review 9.  Clinical implications of chemokines in acute and chronic hepatitis C virus infection.

Authors:  Wonseok Kang; Eui-Cheol Shin
Journal:  Yonsei Med J       Date:  2011-11       Impact factor: 2.759

10.  Association between regulated upon activation, normal T cells expressed and secreted (RANTES) -28C/G polymorphism and susceptibility to HIV-1 infection: a meta-analysis.

Authors:  Zhenghua Gong; Jialin Tang; Tianxin Xiang; Lunli Zhang; Qinghua Liao; Wei Liu; Yalin Wang
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.